Lisa Coker, APRN
Nurse Practitioner · Fort Smith, ARNPI 1265986913
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 368 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,080, 2.8 times the $734 reported in 2021. Among nurse practitioner clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 368 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AstraZeneca$1K
- OPKO Pharmaceuticals, LLC$666
- Bayer$623
- Travere Therapeutics, Inc.$391
- Ardelyx, Inc.$387
- plus $3K from 18 others
What the payments were for
- Food & beverage$7,52298%
- Education$1282%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 87 | $1,813 |
| AstraZeneca(2 entities) | 61 | $1,171 |
| OPKO Pharmaceuticals, LLC | 36 | $666 |
| Bayer | 34 | $623 |
| Travere Therapeutics, Inc. | 18 | $391 |
| Ardelyx, Inc. | 15 | $387 |
| Boehringer Ingelheim | 18 | $350 |
| Aurinia Pharma U.S., Inc. | 12 | $320 |
| GSK | 13 | $283 |
| Novo Nordisk | 13 | $278 |
| Novartis | 11 | $272 |
| Vifor Pharma, Inc. | 11 | $251 |
| Fresenius USA Marketing, Inc. | 10 | $208 |
| Calliditas Therapeutics US Inc. | 7 | $173 |
| ANI Pharmaceuticals, Inc. | 7 | $145 |
| Otsuka America Pharmaceutical, Inc. | 3 | $70 |
| Johnson & Johnson | 3 | $66 |
| Akebia Therapeutics Inc | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Ultragenyx Pharmaceutical Inc. | 1 | $29 |
| AbbVie | 1 | $22 |
| Bard Peripheral Vascular, Inc. | 1 | $21 |
| Ascendis Pharma Endocrinology Inc | 1 | $17 |
| Pharmacosmos Therapeutics Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,650 in reported general payments places this provider in the 95th percentile of 697 nurse practitioner providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 678 | $483,126 |
| FarxigaDapagliflozin Propanediol | 332 | $216,081 |
| KerendiaFinerenone | 160 | $112,171 |
| RayaldeeCalcifediol | 58 | $99,491 |
| XphozahTenapanor Hcl | 26 | $85,291 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $25,635 |
| InvokanaCanagliflozin | 16 | $14,637 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $2,383 |
| Potassium Chloride | 124 | $2,224 |
| Calcium Acetate | 43 | $2,011 |
| Furosemide | 369 | $1,991 |
| Labetalol Hcl | 27 | $1,912 |
| Allopurinol | 142 | $1,326 |
| Tamsulosin Hcl | 121 | $1,294 |
| Hydralazine Hcl | 121 | $1,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $350 | $483,126678 claims |
| AstraZenecaFarxiga, Lokelma | $1,171 | $241,716349 claims |
| BayerKerendia | $623 | $112,171160 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $666 | $99,49158 claims |
| Johnson & JohnsonInvokana | $66 | $14,63716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 697 nurse practitioner providers in Arkansas.
Other nurse practitioner in Fort Smith
- Dakota YoungFort Smith$15K
- Kathleen MilamFort Smith$9K
- Kathleen ToonFort Smith$7K
- Jenny HannaFort Smith$7K
- Jennifer JayFort Smith$6K
- Aida JonesFort Smith$5K
- Jacquelyn IsaacsFort Smith$4K
- Dana ReevesFort Smith$4K
- Merideth HanksRogers$157K
- Angela JonesJonesboro$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.